ClinicalTrials.gg
CompletedNCT03974594Updated Apr 19, 2022

Bioequivalence Study of Trifluridine and Tipiracil Tablets in Colorectal Cancer Patients

A Phase 1 interventional study of Trifluridine and Tipiracil Tablets and TAS-102 in Colorectal Cancer, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-04-19.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Colorectal Neoplasms by Sino Biopharmaceutical Limited — 6 open to participants now, 7 under way, 2 of them phase 3. Colorectal Neoplasms · Sino Biopharmaceutical Limited.

Enrollment
10th of 13
64 · median 72
Started
2019
the only one that year
Phase 1
4 of 13
2 open now
Registered
4th of 13
by date

Among the 13 studies in Colorectal Neoplasms by Sino Biopharmaceutical Limited, this one is the 10th largest by enrollment, is the only one that started in 2019, is one of 4 in phase 1, and was the 4th registered.

Colorectal Neoplasms

6,552 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

6 of the 13 studies in Colorectal Neoplasms by Sino Biopharmaceutical Limited are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Colorectal Neoplasms by Sino Biopharmaceutical Limited, or all of them as a file.
02

Study summary

Trifluridine and Tipiracil Tablets is a nucleoside anti-metabolic and anti-cancer compound developed by Taiho (Dapeng) Co., Ltd., Japan, for the treatment of advanced colorectal cancer that inoperable resection, and progressed or relapsed after standard treatment. This study mainly evaluates bioequivalence, safety and tolerance of Trifluridine and Tipiracil Tablets in colorectal cancer patients.

03

Conditions studied

  • Colorectal Cancer
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18-70 years old, ≥ 3 months.
  2. confirmed colon or rectal adenocarcinoma.
  3. Has not received anti-tumor therapy before 4 weeks of first dose or Traditional Chinese Medicine anti-tumor therapy before 2 weeks of first dose.
  4. (ECOG) performance status of 0 to 1.
  5. Has ability to take oral medication.
  6. The main organs function are normally, the following criteria are met:

    1. (HB) ≥ 100 g / L;
    2. (ANC) ≥1.5×109/L;
    3. (PLT) ≥ 80 × 109 / L;
    4. Total serum (TBIL) ≤ 1.5 × ;
    5. (ALT) and Aspartate aminotransferase (AST) ≤ 2.5 × ULN (when the liver is invaded,AST ≤ 5×ULN);
    6. Serum creatinine ≤ 132.6 μmol / L.
  7. Male or female subjects should agree to use an adequate method of starting with the first dose of study therapy through 6 months after the last dose of study (such as intrauterine devices , contraceptives or condoms) ;No pregnant or breastfeeding women, and a negative pregnancy test are received within 7 days before the randomization.
  8. Understood and signed an form.

Exclusion criteria

Exclusion Criteria:

  1. Has serious diseases , including but not limited to:

    1. Has diagnosed and/or treated additional within 5 years prior to randomization. Exceptions include carcinoma in situ of cervix, non-melanoma skin cancer and superficial bladder tumor;
    2. Has ;
    3. Has active infection (such as infection caused body temperature ≥ 38 ° C);
    4. Has pleural effusion, pericardial effusion, or ascites requiring recurrent drainage before 4 weeks of first dose;
    5. Has intestinal obstruction, pulmonary fibrosis, renal failure, liver failure or symptomatic cerebrovascular disease;
    6. Has uncontrolled diabetes (fasting blood glucose (FBG) > 10mmol/L);
    7. Has myocardial infarction, severe/unstable angina pectoris, (NYHA) grade III or IV symptomatic congestive heart failure within 12 months prior to first dose;
    8. Has gastrointestinal bleeding;
    9. Has infection, or active or C;
    10. Has a history of organ transplants or disease required therapy;
    11. Has increased risk associated with participating in the study or taking the study drug, or mental disorders may interfere with the results of the study.
  2. Has received any of the following treatments before the first dose:

    1. Has received partial or total gastrectomy;
    2. Has surgery (such as laparotomy, thoracotomy, and laparoscopic resection of the viscera and/or unhealed wounds) within 4 weeks;
    3. Has any study drug within 4 weeks.
  3. Prior therapy with TAS-102.
  4. Has adverse events caused by previous therapy except alopecia that did not recover to ≤ grade 2.
  5. Pregnant or lactating woman.
  6. Subjects who, in the opinion of the investigators, should not participate in the study.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    Trifluridine and Tipiracil Tablets

    Drug: Trifluridine and Tipiracil Tablets

  • Active comparator
    TAS-102

    Drug: TAS-102

Interventions

  • DrugTrifluridine and Tipiracil Tablets

    Trifluridine and Tipiracil Tablets given 20mg orally once under fasting or postprandial conditions per cycle

  • DrugTAS-102

    TAS-102 given 20mg orally once under fasting or postprandial conditions per cycle

06

What researchers measure

Primary outcomes

  1. AUC(0-infinity)

    The AUC(0-infinity) is area under the serum concentration-time curve from time zero to infinite time.

    Time frame: 3 days

  2. AUC(0-t)

    The AUC(0-t) is area under the serum concentration-time curve from time zero to t.

    Time frame: 3 days

  3. Bioequivalence based on Peak Plasma Concentration (Cmax)

    The Cmax is observed maximum serum concentration, taken directly from the serum concentration-time profile

    Time frame: 3 days

Secondary outcomes

  1. Adverse Event

    Security Index

    Time frame: Up to 4 weeks

07

Study locations

1 site
  • Tangdu Hospital,Fourth Military Medical University
    Xi'an, Shanxi 710038, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2019 to primary completion in Jul 2019, 1 month.

Of 269 industry-sponsored phase 1 interventional studies under Colorectal Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 66. This study's 1 month is below that.

Counting every sponsor, half of 435 studies reached it within 48 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2019
First posted
Jun 5, 2019
StartActual
May 21, 2019
Primary completionActual
Jul 16, 2019
CompletionActual
Jul 16, 2019
Last update
Apr 19, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 19, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03974594
Responsible party
Sponsor
First posted
Jun 5, 2019
Start date
May 21, 2019
Primary completion
Jul 16, 2019
Completion
Jul 16, 2019
Last update
Apr 19, 2022

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion